IHAM
GILD icon

Integral Health Asset Management’s Gilead Sciences GILD Stock Holding History

Integral Health Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,000
Closed -$13.9M – 102
2026
Q1 		$13.9M Buy
+100,000
New +$14M 0.67% 36
2025
Q2 		– Sell
-175,000
Closed -$19.6M – 87
2025
Q1 		$19.6M Sell
175,000
-25,000
-13% -$2.58M 2.09% 11
2024
Q4 		$18.5M Buy
+200,000
New +$18M 1.57% 23
2023
Q1 		– Sell
-120,000
Closed -$10.3M – 80
2022
Q4 		$10.3M Buy
+120,000
New +$9.5M 2.16% 19

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Integral Health Asset Management's GILD Position: Q2 2026 in Review

Integral Health Asset Management sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 100,000 shares — an estimated $13.9M sold.

Integral Health Asset Management first reported a position in GILD in Q4 2022 and held it in 4 quarters. The position peaked at $19.6M in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Integral Health Asset Management reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Integral Health Asset Management sold 100,000 Gilead Sciences shares in Q2 2026, an estimated $13.9M.
  • Integral Health Asset Management first reported a position in Gilead Sciences in Q4 2022 and held it in 4 quarters.
  • Integral Health Asset Management's Gilead Sciences position peaked at $19.6M in Q1 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.